Home » stock rating

stock rating

Oct 04, 2016

First Analysis Initiates Coverage of NeoGenomics at Overweight

The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.

Jan 05, 2016

GenomeWeb Index Rises 5 Percent in 2015, Led by PacBio; Fluidigm Leads Decliners

There were more winners than losers in the 2015 GWDN Index, but some lost big.

Dec 14, 2015

Raymond James Downgrades Quidel's Stock

The bank downgraded Quidel's shares to market perform and trimmed its Q4 revenue forecast due to a mild flu season.

Sep 02, 2015

Barclays Initiates Coverage on Genomic Health, Quidel, Cepheid; Upgrades Hologic

The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.

May 21, 2015

Investment Banks Downgrade Bruker on Resignation of CFO

Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.

Jun 20, 2014

Piper Jaffray Initiates Coverage of Veracyte with Overweight Rating

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.

Sep 18, 2013

Piper Jaffray Initiates Coverage of PerkinElmer with Overweight Rating

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has initiated coverage of PerkinElmer with an Overweight rating and a $46 price target.

Jan 22, 2013

Analysts Speculate on Potential Life Technologies Sale

NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer, investment firm William Blair today downgra

Jan 22, 2013

Mizuho Downgrades BD to Neutral

NEW YORK (GenomeWeb News) – Mizuho Securities analyst Peter Lawson today downgraded the stock of Becton Dickinson from Buy to Neutral.

Dec 06, 2012

Goldman Sachs Resumes Coverage of Danaher with Neutral Rating

NEW YORK (GenomeWeb News) – Goldman Sachs today resumed coverage of Danaher with a Neutral rating and a 12-month price target of $57.

Pages

The Scan

DNA Defense Not Convincing

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Keep on Brushing

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Panda Gut Seasonality

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

This Week in PLOS

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.